News >

Wakelee Highlights Latest Treatment Strategies in EGFR+ NSCLC

Brandon Scalea
Published: Friday, Sep 21, 2018

Heather A. Wakelee, MD

Heather A. Wakelee, MD
Novel treatments and strategies continue to emerge in the treatment paradigm for patients with EGFR–positive non–small cell lung cancer (NSCLC), explained Heather Wakelee, MD.

¬positive NSCLC.

OncLive: Can you highlight some of the latest advances in EGFR-positive lung cancer?

Wakelee: There is a lot happening in the EGFR space. We now have several first-generation drugs and a couple of second-generation drugs. Third-generation osimertinib has also been FDA approved. Most of the recent data that have been very interesting are the direct comparisons. Until very recently, we went for many, many years without having direct comparisons of different TKIs in the first-line setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication